StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a report released on Monday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Down 1.7 %
Shares of TTNP stock opened at $3.40 on Monday. Titan Pharmaceuticals has a one year low of $3.03 and a one year high of $14.80. The stock has a fifty day moving average price of $3.54 and a 200 day moving average price of $4.71.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last issued its earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Oracle Announces Game-Changing News for the AI Industry
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
